Wegovy Cost in 2026: What You'll Pay, Month by Month

You've probably seen the headlines: Wegovy costs nearly $1,000 a month. And then someone on Reddit says they're paying $25 with insurance. So which is it?

The honest answer: it depends — on your insurance, your dose, whether you qualify for savings programs, and increasingly, whether you're open to the new oral version or alternatives like Foundayo. The GLP-1 pricing landscape has shifted dramatically since oral Wegovy launched in January 2026, and there are more options now than ever.

Let's break down every number you need to know, so you can plan your budget before walking into that first appointment.

The Wegovy List Price: $936/Month

Let's start with the sticker shock. Novo Nordisk's list price for injectable Wegovy is $1,349.02 per month (or $936 after typical PBM rebates). That's the number before insurance, coupons, or any other discounts.

Here's what each dose level costs at list price:

Unlike in some countries where pricing varies by dose, in the US, all dose levels cost the same list price. The dose escalation schedule takes about 16-20 weeks, and you pay the same amount throughout.

But almost nobody pays list price. The real question is: what do people actually pay?

What People Really Pay: The Insurance Reality

The out-of-pocket cost for Wegovy varies wildly depending on your insurance situation. Here's a realistic breakdown based on 2026 data:

With Commercial Insurance (Employer-Sponsored):

• If your plan covers weight management drugs: $25-$150/month copay is common
• Some plans require step therapy (trying lifestyle changes or older drugs first)
• Prior authorization is almost always required
• Your doctor needs to document BMI ≥30 or BMI ≥27 with comorbidities
• Roughly 50-60% of commercial plans now cover GLP-1s for weight loss (up from ~40% in 2024)

With Medicare:

• As of the Treat and Reduce Obesity Act provisions in 2025, Medicare Part D began covering anti-obesity medications for qualifying beneficiaries
• Copays vary by plan but typically $50-$200/month under the new coverage
• Coverage still requires BMI criteria and prior authorization

Without Insurance:

• List price: $1,349/month
• Novo Nordisk Patient Assistance Program: $0/month for qualifying low-income patients (household income ≤400% federal poverty level)
• Novo Nordisk savings card: up to $225 off/month for eligible commercially insured patients, bringing cost to roughly $0-$500/month

💡 Pro tip: Even if your insurance initially denies coverage, about 40% of appeals are successful. Have your doctor submit a prior authorization with documented BMI, comorbidities, and failed lifestyle interventions. Persistence pays off.

Oral Wegovy: What $149/Month Really Means

This is the biggest pricing story of 2026. In January 2026, Novo Nordisk launched oral semaglutide 25 mg (brand name: oral Wegovy) in the United States, priced at a list price equivalent to roughly $149/month after typical PBM discounts.

That's not a typo. The oral version costs about 84% less than the injectable.

Here's why this matters:

• No injections — it's a daily tablet taken on an empty stomach
• Much lower price point — designed to compete with compounded semaglutide and GLP-1 alternatives
• Similar efficacy — the OASIS clinical program showed oral semaglutide 25 mg achieved about 15-17% weight loss, comparable to injectable Wegovy
• Wider access — the lower price and pill format remove two of the biggest barriers to GLP-1 therapy

The catch: You need to take it first thing in the morning on an empty stomach, with no more than 4 ounces of plain water, and then wait at least 30 minutes before eating, drinking, or taking other medications. The bioavailability of oral semaglutide is only about 1%, so absorption conditions need to be precise.

Dosing schedule for oral Wegovy:

• Start at 3 mg daily for 4 weeks
• Increase to 7 mg for 4 weeks
• Then 14 mg for 4 weeks
• Maintenance dose: 25 mg daily

At $149/month, oral Wegovy is reshaping the entire cost conversation around GLP-1 weight loss drugs. For many people, the math now works even without insurance coverage.

Mounjaro (Tirzepatide): The Other Big Option

Mounjaro (tirzepatide) by Eli Lilly is Wegovy's main competitor. It's a dual GLP-1/GIP receptor agonist, and the SURMOUNT trials showed even greater weight loss — up to 22.5% at the highest dose — compared to Wegovy's ~15%.

Mounjaro pricing in the US:

Mounjaro's list price is somewhat lower than injectable Wegovy. More importantly, Eli Lilly's savings card has been aggressive — many commercially insured patients have been paying as little as $25/month.

Mounjaro vs. Wegovy cost comparison:

• List price: Mounjaro ($1,023) vs. injectable Wegovy ($1,349) — Mounjaro is ~24% cheaper
• With insurance: Both typically $25-$150/month (varies by plan)
• Without insurance: Mounjaro savings card often brings cost to $550-$600/month vs. Wegovy at ~$936

🧮 When you compare cost per percent of body weight lost, the numbers get interesting. Wegovy at $936/month for ~15% weight loss works out to about $62/month per percentage point. Mounjaro at $1,023/month for ~22.5% is about $45/month per percentage point. On a pure efficiency basis, Mounjaro offers more bang for the buck.

Foundayo (Orforglipron): The Newcomer to Watch

Eli Lilly's Foundayo (orforglipron) received FDA approval in late 2025 and launched in early 2026 as the first non-peptide, oral GLP-1 receptor agonist. This is a different molecule from semaglutide — it's a small molecule that doesn't require the special absorption-enhancing formulation of oral Wegovy.

Foundayo pricing:

• List price: approximately $149-$349/month (depending on dose)
• Starting dose: 12 mg daily
• Maintenance dose: 36 mg or 72 mg daily
• Can be taken with or without food — a major convenience advantage over oral Wegovy

Why Foundayo matters for pricing:

1. It's designed as a mass-market oral GLP-1 from the start
2. No injection, no strict fasting requirements
3. Priced to compete directly with oral Wegovy
4. ATTAIN trial data showed ~14-15% weight loss at the highest dose — comparable to injectable Wegovy

The GLP-1 market went from one expensive injectable option in 2021 to at least four viable options (injectable Wegovy, oral Wegovy, Mounjaro, Foundayo) by early 2026. That competition is already putting downward pressure on prices.

The Complete Cost Picture: What You'll Spend Beyond the Drug

The medication itself is just one part of the equation. Here's what a full year of GLP-1 therapy really adds up to:

First-Year Costs (Injectable Wegovy, with typical insurance):

• Monthly medication copay: $50-$150 × 12 = $600-$1,800
• Initial consultation (obesity medicine specialist): $200-$400
• Follow-up visits (quarterly): $75-$150 × 4 = $300-$600
• Lab work (metabolic panel, thyroid function, etc.): $100-$300 (2-3 times/year)
• Sharps disposal container: $10-$20

Total first-year cost with insurance: approximately $1,200-$3,100

First-Year Costs (Without Insurance, Injectable Wegovy):

• Medication: $936 × 12 = $11,232
• Doctor visits: $500-$1,000
• Lab work: $200-$500

Total first-year cost without insurance: approximately $12,000-$12,700

First-Year Costs (Oral Wegovy, Without Insurance):

• Medication: ~$149 × 12 = $1,788
• Doctor visits: $500-$1,000
• Lab work: $200-$500

Total first-year cost for oral Wegovy without insurance: approximately $2,500-$3,300

That last number is why oral Wegovy is such a big deal. Even without any insurance, you're looking at roughly the same annual cost as injectable Wegovy with good insurance.

Can You Stop Paying Eventually? The Long-Term Question

One of the biggest cost concerns is whether this is a lifelong commitment. The research is nuanced:

• STEP 4 trial (2022): Patients who stopped Wegovy after 20 weeks regained about two-thirds of lost weight within a year
• STEP 5 trial (2023): Patients who continued Wegovy for 2 years maintained their weight loss, with average total loss of 15.2%
• Some clinicians are now exploring "dose reduction" strategies — maintaining on lower doses (1.0 mg or 1.7 mg) long-term rather than the full 2.4 mg, which could reduce monthly costs by 20-30%

The honest reality: most people who achieve significant weight loss on GLP-1 drugs will need some form of ongoing treatment to maintain it. That might mean a lower dose, switching to a cheaper oral option, or periodic "booster" cycles. The idea of a short course followed by permanent weight maintenance works for some people, but not for the majority.

If you're planning financially, budget for at least 12-18 months of continuous therapy, and then potentially a lower-cost maintenance approach afterward.

Compounded Semaglutide: The Cheap Option That's Disappearing

You've probably heard about compounded semaglutide — the $100-$300/month versions sold by telehealth companies and compounding pharmacies. Here's where things stand in 2026:

• The FDA declared semaglutide was no longer in shortage in late 2024
• This triggered the legal basis for FDA enforcement against compounders
• Several major telehealth platforms have transitioned away from compounded semaglutide
• Some compounding pharmacies still offer it in certain states, but the legal landscape is increasingly uncertain
• Quality and dosing consistency have always been concerns with compounded versions

With oral Wegovy at $149/month, the price gap between branded and compounded has narrowed significantly. For most people, the branded oral option now makes more financial sense when you factor in quality assurance and legal certainty.

Insurance Tips: Maximizing Your Coverage

Here's a practical playbook for getting the best insurance coverage for Wegovy or any GLP-1:

Before Your First Appointment:

1. Call your insurance company and ask: "Does my plan cover anti-obesity medications? Specifically, semaglutide (Wegovy) or tirzepatide (Mounjaro)?"
2. Ask about prior authorization requirements — what documentation does your doctor need to submit?
3. Check if your plan has a step therapy requirement (e.g., try metformin first)
4. Look up your plan's formulary — some plans prefer Mounjaro over Wegovy or vice versa

At Your Doctor's Visit:

1. Make sure your BMI is documented in the chart (≥30, or ≥27 with comorbidities)
2. Ask your doctor to note all relevant comorbidities: sleep apnea, hypertension, type 2 diabetes, PCOS, osteoarthritis, NAFLD/NASH
3. Have your doctor document previous weight loss attempts (diet, exercise, other medications)

If You're Denied:

1. Ask for the denial in writing with the specific reason
2. File a formal appeal — your doctor's office can usually help with this
3. Include clinical evidence (STEP trial data, your personal health history)
4. Consider contacting your state's insurance commissioner if the appeal is denied
5. Check if your employer's HR department can advocate for coverage changes at the next plan renewal

Other Money-Saving Strategies:

• Manufacturer savings cards: Both Novo Nordisk and Eli Lilly offer them; check wegovy.com and mounjaro.com
• Patient assistance programs: For uninsured or underinsured patients with income below certain thresholds
• GoodRx and similar platforms: Can sometimes find lower cash prices at specific pharmacies
• HSA/FSA accounts: GLP-1 medications prescribed for weight loss can typically be paid with pre-tax health savings

Tracking Your Investment: Making Every Dollar Count

When you're spending $150-$1,000+ per month on medication, you want to make sure it's actually working. This is where disciplined tracking becomes essential.

Tools like the Blueshot app can help you track your injection schedule, weight trends, food intake, and side effects in one place. When you have clear data showing your progress (or lack thereof), you're in a much better position to have productive conversations with your doctor about whether to continue, adjust doses, or try a different medication.

Some practical tracking habits:

• Weigh yourself at the same time daily (morning, after bathroom, before eating)
• Log any side effects with severity ratings
• Track measurements beyond weight: waist circumference, how clothes fit
• Note energy levels and hunger patterns — these shift before the scale does

The Price Trajectory: Where Are GLP-1 Costs Headed?

Looking at the market dynamics, there are strong reasons to expect GLP-1 costs to keep falling:

Downward Pressure:

• Oral formulations (oral Wegovy at $149/month, Foundayo at $149-$349) setting new price anchors
• At least 5-6 new GLP-1 or GLP-1 combination drugs in late-stage development
• Insurance coverage expanding (more negotiating leverage for PBMs)
• Political pressure: GLP-1 pricing has become a campaign issue
• Generic semaglutide could arrive as early as 2031-2032 when key patents expire

Upward Pressure:

• Massive demand continues to strain supply chains
• Novo Nordisk investing billions in manufacturing capacity ($6 billion announced in 2025)
• Premium pricing remains feasible as long as demand exceeds supply

Realistic forecast: The effective cost of GLP-1 therapy for the average American is likely to drop to the $100-$200/month range within 2-3 years, driven by oral options, competition, and expanding insurance coverage. The $1,000/month era of injectable-only pricing is effectively over for new patients choosing oral formulations.

Wegovy Pricing Around the World

For context, here's how injectable Wegovy pricing compares globally:

The US has the highest list price but also the most developed savings/assistance program infrastructure. The effective out-of-pocket cost for an insured American can actually be lower than in countries with universal healthcare that don't cover the drug.

Bottom Line: What Should You Budget?

Here's the simplest way to think about it in 2026:

If you have insurance that covers GLP-1s: Budget $50-$150/month for medication plus $100-$200/quarter for doctor visits and labs. Annual cost: roughly $1,000-$2,500.

If you're paying cash: Choose oral Wegovy ($149/month) or Foundayo ($149-$349/month) over injectable options. Annual cost: roughly $2,500-$5,500 including medical visits.

If budget is very tight: Look into manufacturer patient assistance programs (potentially $0), check if your state Medicaid covers anti-obesity meds, or talk to your doctor about starting on a lower-cost GLP-1 option.

The cost of GLP-1 therapy is real, but it's come down dramatically from even two years ago. With oral options, expanded insurance coverage, and growing competition, effective weight management medication is more accessible than it's ever been. The key is to do your homework on insurance coverage and savings programs before your first appointment — a little research upfront can save you thousands over the course of treatment.

使用 Blueshot 开始管理 GLP-1

AI 指导、注射计划和体重追踪一站式管理